The broad-spectrum CKI flavopiridol displayed promising preclinical results in multiple tumor cell types [32–35], but it exhibited adverse effects and high toxicity in early-phase clinical trials [36]; furthermore, it did not meet expectations with regard to efficacy against most tumor types, with the exception of leukemia [34, 37, 38]. This evidence concerns the gene CHKA and neoplasm.